Scancell (LON:SCLP) Shares Up 7% Following Insider Buying Activity

Shares of Scancell Holdings plc (LON:SCLP) shot up 7% during trading on Wednesday following insider buying activity. The company traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). 1,065,551 shares changed hands during mid-day trading, an increase of 21% from the average session volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.12).

Specifically, insider Martin Diggle purchased 44,944 shares of the stock in a transaction on Tuesday, May 20th. The shares were purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,429.48).

Scancell Stock Down 1.0%

The business has a 50-day simple moving average of GBX 9.38 and a two-hundred day simple moving average of GBX 10.21. The stock has a market capitalization of £102.54 million, a P/E ratio of -15.18 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.